Amentoflavone suppresses amyloid β1–42 neurotoxicity in Alzheimer's disease through the inhibition of pyroptosis
ConclusionAF inhibits Aβ1-42-induced neurotoxicity in animal and cellular models through AMPK/GSK3β-mediated pyroptosis suppression. Our results highlight AF as a clinical compound for the prevention and treatment of AD.
Condition: Alzheimer's Disease Interventions: Drug: Tricaprilin; Drug: Placebo Sponsor: Cerecin Not yet recruiting
Publication date: Available online 4 December 2019Source: The Lancet NeurologyAuthor(s): Lon Schneider
Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer's drug aducanumab, which the U.S. biotech company had declared a failure earlier this year.
A study found that the drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's and other forms of dementia
In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72.MethodsIn this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death,...
DISCUSSION: The preclinical duration of cognitive and behavioral changes approaches the earliest reported biomarker changes. PMID: 31787561 [PubMed - as supplied by publisher]
This study compared different methods for collecting data on falls among people with dementia to identify which is most feasible and accurate. Eighty-three dyads, comprised of a community-dwelling person with dementia and their informal carer, participated in the TAi ChI for people with demenTia (TACIT) trial. Falls were collected prospectively over 6 months using monthly calendars, weekly and monthly telephone interviews, and 3-monthly telephone interviews with the carer. Unique falls identified across the reporting methods were combined, and this total was compared against each reporting method in isolation and combinati...
ConclusionsThis is the first study to demonstrate the presence of oligomeric APP-CTFs in AD mouse models, the levels of which are selectively enriched in endolysosomal compartments including exosomes and amplified by γ-secretase inhibition. Future studies should evaluate the putative contribution of these exosome-associated APP-CTFs in AD onset, progression and spreading.
Birth control pills are among the most effective ways to prevent pregnancy, but only if women faithfully take them every day. Human nature being what it is, nearly half of women admit to missing a pill at least once every three months, and, as a result, about 9% of women on oral contraception become pregnant every year. That number would almost certainly fall if women only had to remember to take the pill once a month or so. That’s why researchers at MIT and Brigham and Women’s Hospital (with support from the Gates Foundation) are trying to create a once-a-month birth control pill. In a paper published today (...